Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Pharvaris BV (PHVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PHVS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -20.13% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 856.88M USD | Price to earnings Ratio - | 1Y Target Price 36.71 |
Price to earnings Ratio - | 1Y Target Price 36.71 | ||
Volume (30-day avg) 41022 | Beta -3.02 | 52 Weeks Range 14.14 - 25.50 | Updated Date 04/1/2025 |
52 Weeks Range 14.14 - 25.50 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.83 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.1% | Return on Equity (TTM) -58.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 519445244 | Price to Sales(TTM) - |
Enterprise Value 519445244 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.38 | Shares Outstanding 54233100 | Shares Floating 19153506 |
Shares Outstanding 54233100 | Shares Floating 19153506 | ||
Percent Insiders 9.49 | Percent Institutions 89.48 |
Analyst Ratings
Rating 4.29 | Target Price 33.71 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pharvaris BV
Company Overview
History and Background
Pharvaris BV is a clinical-stage biopharmaceutical company focused on developing oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-mediated diseases. Founded in 2015, Pharvaris has advanced its lead product candidate, deuroconestat, through clinical trials. They went public on the NASDAQ in 2020.
Core Business Areas
- Pharmaceutical Development: Focuses on researching, developing, and commercializing novel therapies for rare diseases, particularly HAE.
Leadership and Structure
The leadership team includes executives with experience in pharmaceutical development and commercialization. The organizational structure is typical of a biotech company, with research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Deuroconestat: An oral, on-demand bradykinin B2 receptor antagonist being developed for the treatment of hereditary angioedema (HAE) attacks. It is currently in Phase 3 clinical trials. Competitors include CSL Behring (Berinert), Takeda (Takhzyro), BioCryst Pharmaceuticals (Orladeyo) and Pharming (Ruconest). Market share is speculative as the drug is not yet approved. The potential revenue is tied to its ability to displace current HAE treatments.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the rare disease segment, is characterized by high R&D costs, lengthy regulatory approval processes, and potential for significant returns on successful products.
Positioning
Pharvaris is positioning itself as a leader in oral HAE therapies, aiming to provide a convenient and effective treatment option for patients. Their competitive advantage lies in their oral formulation and potential for rapid symptom relief.
Total Addressable Market (TAM)
The global HAE market is estimated to be worth several billion USD annually. Pharvaris aims to capture a significant portion of this market with Deuroconestat.
Upturn SWOT Analysis
Strengths
- Novel oral therapy for HAE
- Strong intellectual property portfolio
- Experienced management team
- Potentially more convenient administration than existing injectables
Weaknesses
- Single product focus (Deuroconestat)
- Reliance on successful clinical trial outcomes
- No currently approved or marketed products
- High cash burn rate typical of development stage biotech
Opportunities
- Expansion into other bradykinin-mediated diseases
- Potential for partnerships and collaborations
- Acquisition by a larger pharmaceutical company
- Positive clinical trial results could drive rapid market adoption
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from existing and emerging HAE therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- CSL (CSLLY)
- TAK (TAK)
- BCRX (BCRX)
- PHAR (PHAR)
Competitive Landscape
Pharvaris is attempting to compete with larger, established pharmaceutical companies in the HAE market. Success depends on Deuroconestat's unique advantages and clinical profile compared to existing therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing R&D spending and clinical trial progress.
Future Projections: Future growth is tied to the regulatory approval and commercial success of Deuroconestat. Analyst estimates vary depending on their assumptions about these factors.
Recent Initiatives: Recent initiatives include advancing Deuroconestat through Phase 3 clinical trials and preparing for potential commercialization.
Summary
Pharvaris is a development-stage biotech company focused on oral HAE therapy. Their strength lies in their novel approach and potentially convenient treatment. The company's weakness is their dependence on Deuroconestat's success. It must be aware of threats such as clinical trial failures and competition. Positive trial results and potential market uptake is needed for the company to thrive.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
BCRX
BioCryst Pharmaceuticals Inc
BCRX
BioCryst Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
VCYT
Veracyte Inc
VCYT
Veracyte Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pharvaris BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-05 | Co-Founder, CEO & Executive Director Mr. Berndt Axel Edvard Modig CPA, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 92 | Website https://pharvaris.com |
Full time employees 92 | Website https://pharvaris.com | ||
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.